iPSC-Based CF Modeling: Advances in Drug Testing Platforms

Study Background and Research Question

Cystic fibrosis (CF) is a hereditary disorder caused by mutations in the CFTR gene, which encodes an anion channel crucial for maintaining airway hydration and mucociliary function. Over 2,000 CFTR variants have been identified, with several hundred implicated in clinical disease and categorized into functional classes based on molecular defects. While recent breakthroughs in CFTR modulator therapies have improved outcomes for most people with CF, a significant subset—particularly those with rare or class 1 variants—remains without effective treatments. The need to develop robust, physiologically relevant preclinical models is particularly acute for this population, where traditional cell line and organoid models have notable limitations.

The reference study (Berical et al., 2022) addresses this challenge by leveraging induced pluripotent stem cell (iPSC)-derived airway epithelial cells from individuals with diverse CFTR genotypes. The central research question is how to adapt and validate functional drug testing platforms using these iPSC-derived models to measure genotype-specific CFTR function and drug responsiveness.

Key Innovation from the Reference Study

The primary innovation lies in the establishment of a multimodal iPSC platform tailored for CF drug screening. Unlike prior approaches that relied on immortalized cell lines or primary tissues, this platform uses iPSC-derived airway epithelial cells representing common and rare CFTR variants from three mechanistically distinct classes of dysfunction. The study adapts two robust in vitro assays—forskolin-induced swelling (FIS) in 3D spheroids and transepithelial ion transport measurements in planar, polarized cultures—to this iPSC context. This enables direct, functional comparisons across patient-specific genotypes, bridging a key translational gap in preclinical CF research (reference).

Methods and Experimental Design Insights

The authors generated a panel of iPSC lines from individuals with well-characterized CFTR mutations, including both common and rare alleles. These iPSCs were differentiated into airway epithelial cells using established protocols, achieving mucociliary differentiation and polarization akin to primary human bronchial epithelial cells (HBECs).

• 3D Spheroid Assay: iPSC-derived epithelial cells were cultured as spheroids, and CFTR function was assessed via forskolin-induced swelling. This assay quantifies CFTR-mediated chloride and fluid secretion, providing a sensitive readout of channel function and modulator efficacy.
• Planar Culture Assay: The second approach involved differentiating iPSC-derived cells at air-liquid interface (ALI), forming planar, polarized mucociliary epithelia. Transepithelial electrical measurements allowed for direct assessment of CFTR-dependent ion transport, mirroring the physiologic context of in vivo airway tissue.

Both assays were adapted and optimized for iPSC-derived cells, with genotype-matched controls and replicates to ensure reproducibility. Importantly, the study validated that these iPSC-derived cultures recapitulate key morphological and functional properties of native airway epithelia.

Protocol Parameters

• iPSC differentiation: Use established airway epithelial differentiation protocols, ensuring mucociliary phenotype confirmation by immunostaining and functional assays.
• Forskolin-induced swelling (FIS): Treat 3D spheroids with forskolin (final concentration typically 5–10 μM; refer to the reference study for specific variant-based optimization).
• ALI culture setup: Seed cells onto permeable supports, establish air-liquid interface, and allow at least 21–28 days for full polarization.
• CFTR modulator testing: Apply modulators at concentrations validated in prior studies (e.g., VX-770, VX-809) and include vehicle and non-CF controls to delineate baseline versus drug-induced effects.

Core Findings and Why They Matter

By deploying these adapted assays, the study demonstrated:

• Genotype-Specific Responses: iPSC-derived airway cells exhibited clear baseline and modulator-responsive differences in CFTR function that reflected the underlying genetic variants.
• Reproducibility and Utility: Both 3D and planar assays reliably distinguished between functional classes of CFTR mutations, matching known pathophysiology and clinical responsiveness.
• Application to Rare Variants: The platform proved effective for variants lacking established therapies, supporting its value for precision medicine and personalized drug screening.

These findings underscore the promise of iPSC-based models for bridging the gap between high-throughput, reductionist cell lines and limited-access primary tissues. By enabling robust cell proliferation assay reagent workflows, this approach can accelerate the identification and optimization of candidate therapies for CF patients with rare or previously intractable variants.

Comparison with Existing Internal Articles

Several internal reviews have highlighted the role of fluorogenic oxidation-reduction indicators, such as Resazurin sodium salt, in optimizing cell viability and cytotoxicity workflows for advanced models. For example, Resazurin sodium salt in Next-Gen iPSC Drug Screening Platforms explores assay strategies that are directly relevant to the iPSC models described in the reference study. These articles emphasize the need for sensitive, reliable metabolic readouts in high-throughput and personalized settings—a requirement echoed by the multimodal iPSC platform. Additionally, Precision Fluorogenic Indicator in Cell Assays discusses troubleshooting and advanced applications for challenging models, such as those encountered in rare CFTR variant screening.

While the reference study did not specifically highlight the use of Resazurin sodium salt as a flow cytometry viability dye, its application in similar high-throughput screening workflows is well established in the literature. The capacity for rapid, non-destructive assessment of cell health and proliferation is particularly valuable in iPSC-based platforms, where maintaining cellular integrity and capturing dynamic responses are critical (see also).

Limitations and Transferability

Despite its strengths, the multimodal iPSC platform has limitations. The differentiation protocols, while robust, may not fully recapitulate the complexity of mature airway tissue in all respects. Inter-individual variability in iPSC lines, differentiation efficiency, and functional maturation can introduce variability. Furthermore, while the assays are adaptable and scalable, translation to other tissue types or disease models requires further validation. Importantly, as noted by the authors, the platform's performance with ultra-rare or novel CFTR variants will depend on the availability of patient-derived samples and on-going assay refinement (reference).

Research Support Resources

To enable robust cell viability and functional assays in similar iPSC-based workflows, researchers can incorporate Resazurin sodium salt (SKU B6098) as a sensitive, fluorogenic oxidation-reduction indicator. This reagent is widely used for assessing cell proliferation and cytotoxicity in high-throughput, flow cytometry, and fluorescence microscopy contexts. As recommended in the product information, freshly prepared Resazurin sodium salt solutions help ensure assay reliability, especially when working with sensitive or primary-derived cell models. While the reference study focused on functional ion transport assays, integrating such viability measurements can further validate and optimize iPSC-based CF modeling platforms, supporting translational research and drug discovery across diverse genetic backgrounds.